Cardiovascular toxicity of molecularly targeted agents.
Strevel
Elizabeth L
EL
The Credit Valley Hospital, Department of Medical Oncology, Mississauga, Canada.
Siu
Lillian L
LL
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000628:therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000628:therapy; D008133:Long QT Syndrome / Q000139:chemically induced / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D018754:Ventricular Dysfunction / Q000139:chemically induced / Q000628:therapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors